Navigation Links
Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
Date:5/28/2009

Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients;

Phase 2 Study Currently Enrolling in 17 Leading U.S. Medical Centers

SAN DIEGO, May 28 /PRNewswire/ -- Celladon Corporation presented today Phase 1 data from the Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID), a First-in-Human Phase 1/2 Clinical Trial, in a scientific symposium at the 12th Annual American Society of Gene Therapy Meeting.

The Phase 1 data showed that MYDICAR(R) had an acceptable safety profile in twelve patients, as determined by study investigators and an independent safety committee. In addition, improvements from baseline to six months were observed across a number of key efficacy parameters important in assessing heart failure status. Efficacy was defined as the mean improvement in at least 2 of 5 domains without any worsening in the remaining domains, including a functional six-minute walk test, oxygen consumption, quality of life questionnaire, biomarker activity and left ventricular size and function.

"We are encouraged by the meaningful improvements in cardiac function and overall condition of patients, findings that we believe demonstrate the return toward normal intracellular calcium cycling and contractility in some of the heart muscle cells of these very sick patients," said Krisztina M. Zsebo, Ph.D., president and chief executive officer. "Our extensive preclinical and clinical investigation to understand the molecular basis of myocardial dysfunction, together with the evolution of safe and efficient gene transfer technology, has placed gene-based therapy for heart failure within reach and yielded valuable insights for the entire field of study."

The Phase 1 open-label, sequential dose escalation, multi-center phase of the trial was designed to investigate safety and biological effects of restoring SERCA
'/>"/>

SOURCE Celladon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
2. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
3. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
4. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
5. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
6. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
7. USAID Provides $5M in Emergency Support as Swine Flu Spreads
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... VIEJO , Kalifornien, 20. Mai 2013 ... bekannt, dass das Unternehmen die CE-Kennzeichnung für ... zur Embolisation von Aneurysmen erhalten hat. Das ... Europa bereits mit der kontrollierten Einführung dieser ... bietet die SL-Produktfamilie auch ein verbessertes Handling, ...
(Date:5/20/2013)... 20, 2013  Atlantic Pharmaceuticals, Inc., a specialty ... a unique technology to deter prescription drug abuse ... Anthony Soscia , has been chosen ... Chronicle ,s Health-Care Heroes Awards. The awards are ... to honor individuals and organizations demonstrating excellence and ...
(Date:5/20/2013)... YORK , LONDON , ... , May 20, 2013 ... of Osteoarthritis and Preference for Minimally Invasive Procedures to ... landscape, and market trends for the six arthroscopy device ... (FMSs), arthroscopy implants, arthroscopy radio frequency systems, and arthroscopy ...
Breaking Medicine Technology:Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 2Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 3Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4
... Oct. 29 Stryker Corporation (NYSE: SYK ... a division of Porex Corporation. Porex Surgical is a ... (PPE) for use primarily in reconstructive surgery of the ... the PPE market with strong brand recognition and considerable ...
... LEIDEN, Netherlands, Oct. 29 Pursuant to the provisions of ... Takeover Bids (Besluit Openbare Biedingen Wft) requiring a public announcement ... offer to provide a status update, Johnson & Johnson (NYSE: ... CRXL ; Swiss Exchange: CRX) provide the following ...
Cached Medicine Technology:Stryker Announces Acquisition of Privately-Held Porex Surgical 2Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer 2Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer 3Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer 4Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer 5
(Date:5/20/2013)... According to a June 2009 Bloomberg ... malpractice amount to approximately $3.6 billion dollars per year ... Improvement estimated that there 15 million incidents of medical ... that everyone who receives any form of medical treatment ... Merriam-Webster defines malpractice as “a dereliction of professional ...
(Date:5/20/2013)... UT (PRWEB) May 20, 2013 ... much-pleaded-for successor to Anne G. Osborn’s 1993 award winning ... one of the all-time bestselling neuroradiology texts. , ... her special touch to make complex topics visually appealing ... aspects of brain imaging together with spectacular pathology examples, ...
(Date:5/20/2013)... at Galveston researchers have been awarded a five-year, $1.8 ... and Stroke to apply the techniques of gene therapy ... pain that arises from a malfunction in the nervous ... for millions of Americans, manifesting itself in a variety ... feel intense discomfort in response to a light touch, ...
(Date:5/20/2013)... Horizon NJ Health, New Jersey’s largest Medicaid ... has earned a Commendable Accreditation status from the ... is a wholly owned subsidiary of Horizon Blue Cross ... Plan Accreditation is a nationally recognized program that evaluates ... provide to their members. Health Plan Accreditation performance results ...
(Date:5/20/2013)... CA (PRWEB) May 20, 2013 This ... around the world will make the pilgrimage to San ... 2nd annual Digital Health Summer Summit produced ... provides a unique forum to showcase the latest digital ... best practices, and network with some of industry’s most ...
Breaking Medicine News(10 mins):Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2Health News:Osborn’s Brain from Amirsys Publishing Receives Doody’s Top Honors 2Health News:Pain, pain, go away 2Health News:Pain, pain, go away 3Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 2Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 3Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 4
... Market Share Expected for Western Drug Companies, According to ... Decision Resources, one of the world,s leading research ... finds that the colorectal cancer drug market in ... $118 million in 2007 to $290 million in 2012. ...
... Quantum Group, Inc. (NYSE Amex: QGP ) is ... health records (EHR) in response to the less than 20% ... to fully subsidize the EHR module of PWeR(TM) to its ... if certain Medicare Advantage membership criteria are met. The ...
... LOMA LINDA, Calif., April 13 Loma Linda ... Journal of Clinical Nutrition compares the effects of ... disease, demonstrating that in healthy individuals, walnuts lower cholesterol ... can reduce the overall risk of coronary heart disease."The ...
... ) announced Monday that AKPR has been hired by Brain Balance(TM) Centers ... . com ) ... to help children with Autism, AD/HD, Dyslexia and other Neurological ... Robert Melillo , author of the recently released book, Disconnected Kids ...
... On April 7, 2009, the Boston District ... CoolTouch Inc. after CoolTouch signed a settlement agreement with Dr. ... in 2004 and relates to the use of lasers for ... and pay royalties on CTEV laser sales and accessories that ...
... a premier medical and surgical equipment supplier, expands its ... ... (Vocus) April 13, 2009 -- DRE, Inc.—recently named a ... of new and professionally refurbished healthcare equipment to include the DRE ...
Cached Medicine News:Health News:Chinese Colorectal Cancer Drug Market Will More Than Double by 2012 2Health News:Quantum and Renaissance Health Systems Take Leadership Role in Advancement of Electronic Health Records in Florida 2Health News:Quantum and Renaissance Health Systems Take Leadership Role in Advancement of Electronic Health Records in Florida 3Health News:Quantum and Renaissance Health Systems Take Leadership Role in Advancement of Electronic Health Records in Florida 4Health News:Quantum and Renaissance Health Systems Take Leadership Role in Advancement of Electronic Health Records in Florida 5Health News:Walnuts and Fish Protect Against Heart Disease in Different Ways, According to Newly Published Loma Linda University Research 2Health News:Brain Balance(TM) Centers Picks Adam Kluger Public Relations (AKPR) to Help Promote New Book and Atlanta Event to Raise Awareness About Revolutionary New Way to Treat Learning Disorders; Atlantic Recording Artist/Country Music Star Zac Brown and Dr. Rober 2Health News:CoolTouch Inc. Settles Diomed Lawsuit, Files Re-examination Request for Cynosure '873 Patent 2Health News:DRE Medical Equipment Adds Compact Fetal Monitors to Its Product Lineup 2Health News:DRE Medical Equipment Adds Compact Fetal Monitors to Its Product Lineup 3
Used to establish a percutaneous tract into the renal pelvis for catheter placement or stone manipulation. Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
... Used for catheter positioning and exchange ... of the wire guide coils allows utilization ... a smooth transition to a very flexible ... guide is the most rigid coiled wire ...
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: